GW 501516

GW 501516 (also known as Cardarine or Endurobol) is a PPARδ receptor agonist that was originally developed for its potential therapeutic applications in a variety of diseases, including cardiovascular disease, diabetes, and obesity. However, it was discontinued due to potential health risks and is now often used in the bodybuilding community for its fat-burning effects.

History

GW 501516 was first synthesized in the 1990s by a collaboration between pharmaceutical companies GlaxoSmithKline and Ligand Pharmaceuticals. It was initially developed as a potential treatment for metabolic and cardiovascular diseases. However, during the phase II clinical trials, it was found to cause cancer in animal studies, leading to the discontinuation of its development.

Mechanism of Action

GW 501516 acts as a selective agonist of the PPARδ receptor, a type of nuclear receptor that plays a crucial role in regulating cellular metabolism. By activating this receptor, GW 501516 enhances the oxidation of fatty acids and decreases the production of glucose in the liver, which can lead to improved insulin sensitivity and reduced levels of cholesterol and triglycerides.

Use in Bodybuilding

Despite its potential health risks, GW 501516 has gained popularity in the bodybuilding community due to its ability to increase endurance and promote fat loss. However, it is important to note that the use of this substance is not approved by any regulatory authority and is associated with serious health risks.

Health Risks

The use of GW 501516 is associated with several health risks. Most notably, it has been found to cause cancer in animal studies. Other potential side effects include liver damage, skin rashes, and eye irritation.

Legal Status

GW 501516 is not approved for use in humans by any regulatory authority, including the FDA and the WADA. It is also listed as a prohibited substance by many sports organizations.

See Also

• Selective androgen receptor modulator
• Performance-enhancing substance